CD19 and breast cancer: The percentage and absolute number of CD19+CD24+CD38+ Bregs were reduced in the PD-L1hi BC blockade group compared to the PD-L1hi BC and control groups under DR or IDR culture conditions (P < 0.05 for all; Figure 5D).